Eli Lilly predicts possible launch of obesity drug in 2023
The US-based company hopes to launch Wegovy-competitor tirzepatide for obesity this year or early next year.
by marketwire, translated by daniel pedersen
Novo Nordisk’s relaunch of obesity drug Wegovy might soon face competition from Eli Lilly’s tirzepatide, which is currently approved for type 2 diabetes treatment under brand name Mounjaro and could soon be authorized to treat obesity as well.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly expects 2023 revenue to pass USD 30bn mark
For subscribers
.jpg&w=384&q=75)
